1 Hepatitis B infection is a pressing global health concern as up to 25% of affected patients reportedly die as a result of disease progression to cirrhosis and hepatic failure with accompanying hepatocellular carcinoma (HCC). 1 As patients with significant fibrosis are particularly susceptible to these complications, it is important to accurately assess liver fibrosis and determine the appropriate therapeutic strategy for patients with HBV, including the optimal timing for antiviral therapy.
Although liver biopsy provides important information regarding the severity of necro-inflammatory activity and liver fibrosis, it is often limited by invasiveness and pain, sampling error, and inter-observer disparity. 2 Thus, simple and reliable non-invasive methods to estimate liver fibrosis and HBV progression are needed, such as hyaluronic acid (HA), type IV collagen 7S, aspartate aminotransferase (AST)-toplatelet ratio index (APRI), and fibrosis-4 (FIB-4) index. 3, 4 as a novel marker to assess liver fibrosis using the glycan "sugar chain"-based immunoassay.
5 WFA + -M2BP was first found to predict liver fibrosis in chronic hepatitis C patients. Soon afterwards, Umemura et al. described that WFA + -M2BP levels were related to liver fibrosis stage and prognosis in patients with primary biliary cirrhosis (PBC). 6 Later studies validated serum WFA + -M2BP as helpful for assessing the stage of liver fibrosis in patients with non-alcoholic fatty liver disease 7 and autoimmune hepatitis (AIH). 8 In addition, WFA + -M2BP has been found to predict the onset of HCC. Yamasaki et al. concluded that the cumulative incidence of HCC was associated with WFA + -M2BP levels, 9 and Sasaki et al. reported that WFA + -M2BP could be a novel predictor of HCC development after a sustained virological response in patients with chronic hepatitis C treated with interferon (IFN). 10 However, there are no published data to date regarding the usefulness of WFA + -M2BP as a liver fibrosis marker or predictor of HCC in individuals chronically infected with HBV. This study therefore evaluated the ability of serum WFA + -M2BP to detect significant histological fibrosis and analyzed the utility of WFA + -M2BP as a predictor of HCC onset in patients with chronic HBV infection.
METHODS

Patients
A TOTAL OF 157patients chronically infected with HBV who had undergone liver biopsy at Shinshu University (Matsumoto, Japan) between 1998 and 2013 were recruited for this study. Individuals with a history of organ transplantation or concurrent use of immunomodulatory drugs or corticosteroids were excluded from the analysis, as were those co-infected with the hepatitis C virus (HCV) or HIV type 1 or who showed evidence of other liver disease, such as PBC, AIH, alcoholic liver disease, or non-alcoholic fatty liver disease. Thirty-five patients were removed due an unavailability of histological findings or insufficient serum or laboratory data. Ten patients who had already received treatment with IFN or nucleos(t)ide analogues (NAs) at the time of liver biopsy were also excluded. Twenty-four (21%) patients received IFN monotherapy and 63 (56%) patients underwent NA treatment after enrolment. Ultimately, 112 treatment-naïve patients with chronic hepatitis B were enrolled to evaluate for associations of WFA + -M2BP with fibrosis stage and disease progression to HCC. The diagnosis of chronic HBV infection was based on the persistence of hepatitis B surface antigen for more than 6 months.
11 Blood samples were obtained on the same day as the liver biopsy, and separated serum was stored at À20°C. Subjects were followed at regular intervals throughout the observation period. The protocol of this study was approved by the ethics committee of Shinshu University School of Medicine in accordance with the principles of the 64th World Medical Association Declaration of Helsinki in 2013. All patients provided written informed consent.
Laboratory testing
Hepatitis B surface antigen, hepatitis B e antigen, and hepatitis B e antibody were assessed using commercially available enzyme immunoassay kits. 12 Serum levels of HBV DNA were quantified using the COBAS TaqMan HBV Test version 2.0 (Roche Diagnostics, Tokyo, Japan) having a dynamic range of 2.1-9.0 log copies/mL. Serum alanine aminotransferase (ALT), AST, and other relevant biochemical evaluations were carried out using standard methods.
Detection of serum WFA + -M2BP
Quantification of WFA + -M2BP was based on a lectinantibody sandwich immunoassay using the fully automatic immunoanalyzer HISCL-2000i (Sysmex, Hyogo, Japan). 5 The measured values of WFA + -M2BP conjugated to WFA were then indexed with the obtained values using the equation:
Cut-off index
with WFA + -M2BP as the serum sample value, PC as the positive control, and NC as the negative control. The positive control was supplied as a calibration solution preliminarily standardized to yield a COI value of 1.0. 13 
Fibrosis markers
Serum HA and type IV collagen 7S levels were measured by commercially available enzyme-linked immunosorbent assays. The APRI was calculated as:
AST=upper limit of normal; 40 IU=LÞ
The FIB-4 index was calculated as:
Predictive abilities of WFA +
Histological evaluation
Liver biopsies were carried out on all patients by percutaneous sampling of the right lobe with a 14-gauge needle as reported previously. 16 All samples were 1.5 cm or more in length. Formalin-fixed, paraffin-embedded specimens were prepared and used for subsequent histopathological and immunohistochemical studies. Sections measuring 4 μm were cut from each paraffin block and stained with hematoxylin-eosin, periodic acid-Schiff after diastase digestion, and Azan-Mallory staining. All liver biopsy samples were independently evaluated by two investigators who were blinded to the clinical data. Liver fibrosis stage was assessed according to the revised Inuyama classification of chronic hepatitis 17 as: F0, no fibrosis; F1, portal fibrosis without bridging; F2, portal fibrosis with rare bridging; F3, abundant bridging without cirrhosis; and F4, cirrhosis.
Statistical analyses
Statistical analyses and data visualization were carried out using IBM SPSS Statistics version 23.0 (IBM, Chicago, IL, USA) and StatFlex version 6.0 (Artech, Osaka, Japan) software. Data are presented as median ± interquartile range for continuous variables. Groups were compared using the χ 2 -test for categorical variables. Correlations between fibrosis stage and serum WFA + -M2BP values were analyzed by means of Spearman's rank test. Diagnostic accuracy was evaluated using the area under the receiver-operating characteristic (ROC) curve (AUROC). Cut-off values were identified by the Youden index, and the nearest clinically applicable value to the cut-off was considered as the optimal cut-off value for clinical convenience. Hepatocellular carcinoma incidence rates were estimated by the KaplanMeier method and assessed using log-rank tests. Multivariate analysis was carried out using the Cox proportional hazards model with stepwise method. All statistical tests were two-sided and evaluated at the 0.05 level of significance.
RESULTS
Baseline clinical characteristics
T HE BASELINE CLINICAL characteristics of our cohort are summarized in Table 1 . Of the 112 enrolled patients, 72 were male and 40 were female. Median age was 47 years. The average follow-up period was 173 weeks. During the observation period, 24 (21%) patients received IFN monotherapy and 63 (56%) underwent NA treatment. Fifteen (13%) cases became complicated with HCC during follow-up. Of these, 14 (93%) received NAs.
Based on histological findings, the number of patients with fibrosis stage F0, F1, F2, F3, and F4 was 4, 36, 26, 24, and 22, respectively.
Liver fibrosis estimation by WFA-M2BP values 1.14, 1.03, and 1.64, respectively. We observed a significant association between WFA + -M2BP value and fibrosis stage (r = 0.3725, P = 0.001).
Correlation of liver fibrosis with other non-invasive markers
The correlation coefficients between WFA + -M2BP and other non-invasive markers (HA, type IV collagen 7S, APRI, FIB-4, serum albumin, and platelet count) are shown in Figure 2 . Moderate but statistically significant correlations were found between WFA + -M2BP and HA (r = 0.425, P < 0.0001), type IV collagen 7S (r = 0.377, P = 0.0001), APRI (r = 0.267, P < 0.0045), FIB-4 (r = 0.316, P = 0.0007), and serum albumin (r = À0.436, P < 0.0001), but not platelet count.
Diagnostic ability of WFA + -M2BP for liver fibrosis stage
We next assessed the diagnostic ability of WFA + -M2BP to determine fibrosis stage using ROC analysis. The AUROC of WFA + -M2BP to diagnose F2-4, F3-4, and F4 was high at 0.713, 0.658, and 0.689, respectively (Fig. 3) .
The ROC curves of the other fibrosis markers are presented in Figure 4 /L were determined as independent predictive factors for complicating HCC ( Table 2 ). The cumulative incidence rate of HCC was significantly different among subjects with an independent risk factor of WFA + -M2BP ≥0.71 (P = 0.020, log-rank test) (Fig. 5) . 
DISCUSSION
S ERUM WFA
+ -M2BP HAS been described as a superior non-invasive marker for estimating liver fibrosis in several chronic liver diseases. To the best of our knowledge, this is the first study to show that WFA + -M2BP can also be a good indicator of fibrosis in patients with chronic HBV infection. Our results showed a significant correlation between WFA + -M2BP value and liver fibrosis that was comparable to other reported serum fibrosis markers, particularly HA, type IV collagen 7S, and serum albumin.
However, compared with serum WFA + -M2BP values detected in patients with other chronic liver diseases, those in our HBV patients tended to be lower throughout the progression of liver fibrosis; median WFA + -M2BP for fibrosis stage F2 was 0.97 in HBV patients versus 3.86 in HCV patients, 2.1 in AIH patients, 2.0 in PBC patients, and 1.07 in NASH patients. [6] [7] [8] 18 Artini et al. also found that total M2BP expression levels were higher in HCV-positive than in HCV-negative patients throughout the progression of Yamasaki et al. 9 observed a greater incidence of HCC development in patients with chronic hepatitis C who showed higher serum WFA + -M2BP levels, even after stratification by liver fibrosis grade, for yet undetermined reasons. Total M2BP was first identified by Iacobelli et al. as a tumor-associated antigen. 21 Mac-2 binding protein is a highly glycosylated secretory protein that principally mediates cell-to-cell proliferation and angiogenesis. Several proteomic studies uncovered that WFA + -M2BP also enhanced cell adhesion in the extracellular matrix to promote fibrosis. 19, 22, 23 Therefore, WFA + -M2BP might possess additional characteristics as a tumor-associated antigen that is not associated with liver fibrosis.
The present study has several limitations. It was retrospective and single-center in nature, the liver biopsy for evaluating the degree of liver fibrosis was prone to sampling error, and the sample size was limited. Thus, larger prospective multicenter studies are warranted.
In conclusion, WFA + -M2BP may represent not only a non-invasive and reliable marker for assessing fibrosis stage, but also a predictor of complicating HCC, in patients chronically infected with HBV. 
